Table 5. General symptoms by group (female)
| Gender | Group/dosage (mCi/kg) | The number of animal | General symptoms | Day of administration (day 1), time after administration (hour) |
| 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| Female | V.C./0 | 5 | Asymptomatic | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| T1/2.0 | 5 | Asymptomatic | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| T2/6.0 | 5 | Asymptomatic | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| T3/18.0 | 5 | Asymptomatic | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Gender | Group/dosage (mCi/kg) | The number of animal | General symptoms | Observation period after administration (day) |
| 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| Female | V.C./0 | 5 | Asymptomatic | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| T1/2.0 | 5 | Asymptomatic | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| T2/6.0 | 5 | Asymptomatic | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| T3/18.0 | 5 | Asymptomatic | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 |
| Abnormal findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11) | 11) | 11) | 12) | 12) | 12) |
Hair loss;
Fissure.